Bullish Case: SNAP at $5.675 shows calls outpacing puts by 63%, Helium and market densities both peak near $5.50 with a meaningful $6.00-6.50 shoulder, and market IV (68-121%) sits well above Helium's curve—rich premium that can decay if Q4 ad spend and Snapchat+ momentum hold. Long-dated 2028 $10C volume (IV ~65-73%) signals patient bullish positioning; modest upside toward $6+ compresses vol without needing a trend.

Bearish Case: Term structure is in backwardation (Nov 7 Helium IV 115-129% vs Apr 2027 ~65-73%), signaling acute near-term event risk: Snap is the SOLE defendant in an LA social-harms trial opening next week, Australia is suing Snap over the under-16 ban, and France/Greece regulatory actions threaten teen DAUs. Helium AI forecast is -3.02%, correlation weak (0.1), options volume 5th percentile—thin support if litigation or headlines hit.

Potential Outcomes:

1. Range $5.20-$6.00 (40%): trial stays contained, IV decays from backwardated levels.
2. Adverse trial/regulatory headlines → $4.50-$5.20 (28%): sole-defendant exposure plus Australia suit; Nov 6/7 puts (IV 187-242%) stay bid.
3. M&A/rumor pop toward $6.50-7 (8%): Polymarket only 5% Yes—contrarian catalyst.
4. Monetization beat, drift $6.00-$6.50 (14%): call-heavy volume, Jan 2027 $6C ($0.53-0.58) implies confidence.
5. IV-only spike, price flat (10%): backwardation steepens on trial noise.

November 03, 2026